Loading...
Adjuvant chemotherapy with a fluorinated pyrimidine plus oxaliplatin is the standard treatment for patients with stage III colorectal cancer (CRC) and is also considered for those with high-risk stage II disease.
To compare the effectiveness of adjuvant chemotherapy with either capecitabine alone or capecitabine plus bevacizumab in this setting, investigators conducted an industry-sponsored, international, open-label, phase III trial (QUASAR 2) involving 1941 evaluable CRC patients (median age, 65 years; 57% men) who had undergone potentially curative surgery. Of these, 61%–62% had stage III disease, 38%–39% had high-risk stage II disease, and 12% had rectal primaries.
At a median follow-up of 4.9 years, results were as follows:
Three-year dis…